SPP1 and triple-A syndrome: The Fenofibrate in the Management of Abdominal Aortic Aneurysm (FAME)-2 trial showed that 24 weeks of fenofibrate therapy did not significantly influence the circulating concentrations of AAA-associated proteins including osteopontin and KAL despite reducing serum triglyceride55.